Welcome to
synapcell blog
Engrail Therapeutics - SynapCell Collaboration
ENX-101, a GABAA Receptor α2,3,5-selective Positive Allosteric Modulator, Displays Antiseizure Effects in the GAERS Model of Epilepsy Absence
We are thrilled to share the promising results of a study conducted by Engrail Therapeutics on Epilepsy, in which SynapCell contributed with preclinical EEG testing. This study has just been published in “ENX-101, a GABAA receptor α2,3,5-selective positive allosteric modulator, displays antiseizure effects in rodent seizure and epilepsy models”, Serrats et al. 2025.
As part of a comprehensive set of well-established Epilepsy models, the antiseizure effects of Engrail Therapeutics’ molecule ENX-101 were evaluated in the Genetic Absence Epilepsy Rats from Strasbourg (GAERS*), using in vivo EEG tests in freely moving animals performed by SynapCell.
The results showed that ENX-101 demonstrated efficacy accross multiple rodent seizure and Epilepsy models, and was particularly effective in the GAERS rat, a validated model of Absence Epilepsy, the most common form of idiopathic Generalized Epilepsy. These findings support further evaluation of ENX-101 as a potential antiseizure treatment for patients with Focal and Generalized Epilepsies.
* SynapCell holds the world-exclusive license for the GAERS model since 2007.
Comparison of the effects of ENX-101 and diazepam administered by oral gavage on spikewave discharges in the GAERS genetic rat model of absence seizures:
(A) Time course of the effect of the treatments on spikewave discharge (SWD) counts in successive 20 min epochs beginning 10 min after treatment administration.
(B) SWD rates during the entire post-treatment observation period from 10 min to 130 min after treatment administration expressed as a percent of the baseline rate for all groups. Each treatment group consisted of 4 to 10 rats. ***p<0.001, ****p<0.0001. Error bars show S.E.M.